Evaluation of Olopatadine, a New Ophthalmic Antiallergic Agent with Dual Activity, Using the Conjunctival Allergen Challenge Model
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology
Reference18 articles.
1. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy;Abelson;Surv Ophthalmol,1993
2. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study;Fahy;Eur J Ophthalmol,1992
3. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis;Abelson;J Allergy Clin Immunol,1994
4. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model;Abelson;Ophthalmology,1995
5. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent;Yanni;J Ocular Pharmacol,1996
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparing Intracanalicular and Topical Steroid Use in Patients Undergoing Pterygium Surgery;Eye & Contact Lens: Science & Clinical Practice;2024-02-01
2. Etiology and pharmacotherapy of ocular surface allergic diseases;Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics;2022
3. Comparative observational analysis of clinical outcomes in patients of vernal keratoconjunctivitis treated with eye drops olopatadine or bepotastine besilate;Journal of Medical Evidence;2022
4. Ocular redness – II: Progress in development of therapeutics for the management of conjunctival hyperemia;The Ocular Surface;2021-07
5. Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810;ACS Pharmacology & Translational Science;2020-11-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3